



Marijuana Use During Pregnancy 
 
Marijuana, or cannabis, is the most commonly used illicit substance in the United States. 
On August 29, 2019, the US Surgeon General released an advisory entitled, Marijuana 
Use and the Developing Brain. The advisory is intended to raise awareness of the known 
and potentially harmful effects of marijuana on brain development in infants, children 
and adolescents. Marijuana contains varying levels of delta-9-tetrahydrocannabinol (THC), 
the component responsible for euphoria and intoxication, and cannabidiol (CBD). CBD is 
not intoxicating and does not lead to addiction, however the long-term effects of CBD use 
are largely unknown. 
 
During pregnancy, THC from the maternal bloodstream may enter the fetal brain and 
disrupt the endocannabinoid system. This impacts the formation of brain pathways 
important for decision making, mood and response to stress. Adverse effects for children 
exposed to marijuana prenatally may include hyperactivity, poor cognitive function, and 
other long-term neurologic consequences (Metz & Stickrath, 2015). Marijuana products 
today are much more potent than they were in years past; the amount of THC cultivated 
in marijuana plants has increased three-fold from 1995 to 2014. In this recent advisory, 
the US Surgeon General warns that: “No amount of marijuana use during pregnancy or 
adolescence is known to be safe. Until and unless more is known about the long-term 
impact, the safest choice for pregnant women and adolescents is not to use 
marijuana.” 
 
In 2018, Canada became the second country in the world to legalize marijuana (cannabis) 
on a national level. A recent study from Canada that found that children exposed to 
marijuana in utero had a moderately elevated risk of developing autism spectrum 
disorder. Canadian researchers have published several studies that link marijuana use 
during pregnancy and long term neurodevelopmental sequelae in children. The Canadian 
Institute of Human Development, Child & Youth Health (IHDCYH) has produced an 
educational video for the public that discourages women from using marijuana while 
they are pregnant. 
 
For more information and additional resources on marijuana use during pregnancy, please 
contact: Penny Smith, BSN, RNC-NIC, Neonatal Nurse Specialist, Iowa’s Statewide Perinatal 
Care Program. Email: penny-smith@uiowa.edu. 
 
Iowa Becomes an AIM State 
On September 21, 2020, the Iowa Department of Public Health announced Iowa’s 
enrollment in the Alliance for Innovation on Maternal Health (AIM) Program. AIM is a 
national data-driven maternal safety and quality improvement initiative based on 
interdisciplinary consensus-based practices for improving maternal safety and outcomes. 
The program provides implementation and data support for the adoption of evidence- 
based patient safety bundles. AIM works through state teams and health systems to align 
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IMQCC’s Iowa AIM Kick-Off Conference 
On January 28 & 29, 2021, IMQCC will host a statewide 
AIM kick-off meeting. This conference will be the official 
kick-off for the program in Iowa and will focus on our first 
state-wide initiative: Safe Prevention of the First Cesarean Section and Support of Vaginal 
Birth. The conference agenda will include discussion of the current state of the state with 
regards to Cesarean birth, best practices to support vaginal birth as outlined in the AIM 
bundle, and Quality Improvement strategies to make implementing best practices more 
efficient and effective at your institution. We hope that representation from each of Iowa's 
birthing hospitals will join us, along with public health professionals, stakeholder 
organizations, and patient and community representatives. Hospital teams are encouraged 
to have at least three participants to optimize participation in the break-out sessions. 
 
REGISTER HERE for IMQCC’s Iowa AIM Kick-Off Conference. There is no cost to attend. 
 
For more information regarding the upcoming AIM kick-off and IMQCC, please contact: 
Amy Dunbar, RNC-OB, C-EFM, amy-brandt@uiowa.edu, Stephanie Radke, MD, stephanie- 





Updates from INQC 
 
The collaborative is currently focusing QI efforts on 
the care of newborns with Neonatal Abstinence 
Syndrome (NAS). The incidence of reported NAS has 
increased from 0.3 per 1000 live births in Iowa in 
1999 to 3 per 1000 live births in 2017. Although NAS 
was initially used to describe infants solely 
withdrawing from opiates used by mothers during pregnancy, we now realize that newborns 
can have signs and symptoms of withdrawal from many other drugs, prescribed or illicit, that 
induce dependence during pregnancy. Tools to assess NAS such as the Finnegan or modified 
Finnegan scoring system are complicated with poor inter-observer reliability. Infants with 
NAS are often managed at a higher level of neonatal care which results in increased parent- 
infant separation, more pharmacological intervention, prolonged hospital stays and increased 
costs. 
 
The mission of INQC is to create a guideline which includes potentially better practices for 
management of infants with NAS. The goal of the guideline will be to simplify the evaluation 
process and potentiate the use of nonpharmacologic interventions for early care. Hospital 
teams will partner with parents to help decrease the incidence of separation of newborns 
from their families and to decrease transfers to a higher level of care. Participating hospitals 
will begin data collection for the NAS QI project in January 2021 using the REDCap platform. 
 
If your hospital is not currently engaged in the collaborative and you would like more 
information, please contact Penny Smith, RNC-NIC, penny-smith@uiowa.edu or 
Dennis Rosenblum, MD, dennis.rosenblum@unitypoint.org. Visit INQC website HERE. 
